期刊文献+

吡格列酮对急性心肌梗死左室功能和心肌细胞凋亡的影响 被引量:2

Effect of Pioglitazone on left ventricular function and cardiomyocytes apoptosis after acute myocardial infarction in mice
原文传递
导出
摘要 目的:观察盐酸吡格列酮对急性心肌梗死(AMI)小鼠左室功能与心肌细胞凋亡的影响,研究调节心肌组织过氧化物酶体增殖物激活受体γ(PPARγ)表达对小鼠心肌梗死的作用。方法:结扎C57BL/6小鼠左冠状动脉制作AMI模型,分为非吡格列酮治疗组(非治疗组)和吡格列酮(20mg.kg-1.d-1)治疗组(治疗组),以假手术组作为对照组。HE染色检测组织病理学改变,TTC染色检测梗死面积,脱氧核糖核苷酸末端转移酶介导的缺口末端标记(TUNEL)检测心肌细胞凋亡,Western blot检测PPARγ的表达,观察吡格列酮对上述指标的影响。结果:①经吡格列酮治疗14d后,治疗组小鼠病理组织学改变较非治疗组明显减轻,但心肌梗死面积无显著改变[(32.20±4.59)%∶(33.49±5.38)%,P>0.05]。②与假手术组比较,非治疗组左室舒张末期内径(LVEDD)、左室收缩末内径(LVESD)明显升高(P<0.01),左室射血分数(LVEF)、短轴缩短率(FS)明显降低(P<0.01);与非治疗组比较,治疗组LVEDD、LVESD明显升高(P<0.01),LVEF、FS明显降低(P<0.01),但仍高于假手术组(P<0.01)。③与假手术组比较,小鼠心肌梗死后心肌组织TUNEL阳性细胞率明显增加(P<0.01),经吡格列酮治疗14d后明显减少(P<0.01)。④非治疗组小鼠心肌PPARγ蛋白表达高于假手术组,经吡格列酮治疗14d后蛋白表达量显著增加(P<0.01)。结论:吡格列酮能有效降低小鼠心肌梗死后心肌细胞凋亡,改善左室功能。 Objective:To observe the effect of Pioglitazone on the histological change, the apoptosis level of cardiomyocytes and peroxisome proliferator-activated receptor γ (PPARγ) expression after myocardial infarction (MI) in mice in vivo. Method:MI model of mice was established by ligation of the left coronary artery. MI mice were divided into two groups: AMIA group (without any treatment) and AMIB group (treated with Pioglitazone 20 mg . kg 1 . d 1 ). The mice in sham group underwent the same procedures but without ligating the LAD arte y. The infarct size was assessed by TTC staining and the changes of the cardiac structure after infarction was assessed by HE stain. Left ventricular end-diastolic dimension (LVEDD), left ventricular end-systolic dimension (LVESD), fractional shortening (FS)and left ventricular ejection faction (LVEF) were measured with echocardiography. The apoptosis level was examined with dT-mediated dUTP nick end labeling (TUNEL). The expression of PPARγ protein was examined by Western blot. Result: (1)Fourteen days after treated by Pioglitazone, the myocardial pathology was improved significantly, but infarct size was not changed compared with AMIA group [(32.20 ±4. 59)% vs (33.49±5.38)%, P〉0.05]. (2)Compared with the sham group, LVEDD and LVESD in the AMIA group were reduced greatly (P〈0.01), FS and LVEF were increased (P〈0.01). Fourteen days after treated with Pioglitazone, LVEDD and LVESD in AMIB group were significantly increased, FS and LVEF were decreased (P〈0.01) compared with AMIA group. (3)Compared with the sham group, the TUNEL-positive cell percentage in AMIA group was increased. Compared with the AMIA group, the TUNEL-positive cell percentage in the AMIB group was decreased significantly (P〈0.01). (4)Fourteen days after treated with Pioglitazone, the expression of PPARy was increased obviously in the AMIB group compared with the AMIA group and the sham group (P〈0. 01). Conclusion:Pioglitazone can improve left ventricular function and cardiomyocytes apoptosis of MI in mice.
出处 《临床心血管病杂志》 CAS CSCD 北大核心 2013年第3期227-229,共3页 Journal of Clinical Cardiology
基金 武汉市卫生局科技项目(No:武卫[2007]43号)
关键词 心肌梗死 吡格列酮 细胞凋亡 过氧化物酶体增殖物激活受体-Γ myocardial infarction Pioglitazone apoptosis peroxisome proliferator-actuvated receptor-γ
  • 相关文献

参考文献7

  • 1SAM F, SAWYER D B, CHANG D L, et al. Pro- gressive left ventricular remodeling and apoptosis late after myocardial infarction in mouse heart[J]. Am J Physiol Heart Circ Physiol, 2000,48 : 422 - 428.
  • 2CALDWEI.L S H, ARGO C K, AL-OSAIM1 A M. Ther- apy of NAFLD: Insulin Senxmsitizing Agents[J]. J Clin Gas- troenterol, 2006,40 : 61 - 66.
  • 3LEHRKE M, LAZAR M A. The many faces of PPAR- gamma[J]. Ce11,2005,123:993 -999.
  • 4林先和,李隆贵.PPARγ在心血管疾病防治中的临床价值[J].临床心血管病杂志,2004,20(5):316-318. 被引量:7
  • 5EHARA M, HASEGAWA K, ONO K, et al. Acti- vators of PPARc antagonize protection of cardiacmyo- cytes by endothelin-l[J]. Biochem Biophys Res Com- mun,2004,321:345-349.
  • 6CHEN J, LI D, ZHANG X, et al. Tumor necrosis fac tor-alphaindueed apoptosis of human coronary artery en dothelial cells: modulation by the peroxisome proliferator- activated reeeptopgamma ligand pioglitazone[J]. J Card iovasc pharmacol Ther, 2004,9 : 35 - 41.
  • 7李健,冯义柏,田莉,郎明健.吡格列酮预处理对大鼠缺血再灌注心肌细胞凋亡和线粒体超微结构的影响[J].临床心血管病杂志,2008,24(8):620-624. 被引量:10

二级参考文献23

  • 1张波,王志农,王军,黄盛东,刘延玲,徐志云,张宝仁.核因子kappaB在早期心肌缺血再灌注损伤中的作用[J].中华实验外科杂志,2004,21(9):1042-1044. 被引量:14
  • 2马世玉,马业新,吴基良,周强.脂质胞壁酸诱导的预适应对自发性高血压大鼠心肌缺血再灌注损伤的保护作用[J].临床心血管病杂志,2007,23(3):210-215. 被引量:1
  • 3Berger J, Moller D E. The mechanisms of action of PPARS. Annu Rev Med,2002,339:953-959.
  • 4Beamer B A, Negri C, Yen C J, et al. Chromosomal localization and partial genomic structure of the human peroxisome proliferator activated receptor-γ (hPPARγ) gene. Biochem Biophys Res Commun,1997,233:756-759.
  • 5Hsu M H, Palmer C N A, Song W, et al. A carboxyl-terminal extension of the zinc finger domain contributes to the specificity and polarity of peroxisome proliferator-activated receptor DNA binding. J Bio Chem,1998,273:27988-27997.
  • 6Desvergne B, Wahli W. Peroxisome proliferator-activated receptors: nuclear control of metabolism. Endocr Rev,1999,20:649-689.
  • 7Olefsky J M. Treatment of insulin resistance with peroxisome proliferator-activated receptor γ agonists. J Clin Invest,2000,106: 467-472.
  • 8Vamecq J, Latruffe N. Medical significance of peroxisome proliferator-activated receptors. Lancet,1999,354: 141-148.
  • 9Jackson S M, Parhami F, Xi X P, et al. Peroxisome proliferator-activated receptor activators target human endothelial cells to inhibit leukocyte-endothelial cell interaction. Arterioscler Thromb Vasc Biol ,1999,19: 2094-2104.
  • 10Neve B P, Fruchart J C, Staels B. Role of the peroxisome proliferator-activated receptors(PPAR) in atherosclerosis. Biochemical Pharmacol,2000,60: 1245-1250.

共引文献15

同被引文献20

  • 1Weidncr N , Folknian J,Pozza t , et al. Tumor angiogcnesis : a n<*w sig-nificant and independent prognostic factor in early-sta^e hn*asl oarri-noma[ J ]. J Natl Cancer lusl, 1992 ,84(24) ; 1875-1887.
  • 2Meier P,Gioekler S,/hindcn K, tM al. {beneficial effect oi recruitahlecollaterals:a lO-vear follow-up study in patients with stiil)le coronaryarlery disease muler^)ing (juanlitative rollateml measurements. Circu-lation ,2007 ,1 16( 9) :975-983.
  • 3Chintalgatlu V , I (arris GS, Akula SM , rt al. PPAK-7 agonists in<iuc(*Ihe expression of VKOK citxi ils HMeplors in (ailluml cardiac myofiliro-l)lasts[ J] . Cardiovasc Us ,2007 ,74( I ) : 140-150.
  • 4Yamakawa K, Hosoi M , Koyania H ,.*t al. IVroxisome [jniliierator acti-vated receptor gamma agonists increase vascular (Mulothelial growlhfacior expression in human vascular smooth must-Ie (;ells[ J ]. Hioclu*niBiophys Kes Conmiun ,2000,271 (3) :571 -574.
  • 5Yue TI TL, Chen J, Bao W , vt al. In vivo myocardial protection i'romischemia/reperfusion injury l>y the pemxisome proliferator activatedreceptor-gamrria agonist rosiglita/onc [ J ]. Circulation, 2001,104(21):2588 -2594.
  • 6Delerive P,Fmcfiail JC,8laels H. Peroxisome proliferator-activated re-cepLors in inflammation (M)ntm![ J ]. J Endocrinol ,2001,169( I ) :453-459.
  • 7Ito 11 ,Nakano A , Kinoshita M , el a!. A peroxisome proliferalor-activa-t('d ret*e{)t(>r-garnma agonist, attt'mmteH myocardial ischcniia/n*|)(*r(u-sioi) injury in a ml modt'l[ J ]. l^tl> Invest ,2003 ,83 (2) : 1715 -1721.
  • 8Rosen CJ. Revisiting the rosiglitazone story-lessons learned[J]. N Engl J Med, 2010,363(9):803-806. doi: 10.1056/NEJMp1008233.
  • 9Ksul S, Bolger AF, Herrington D, et al. Thiazolidine-dione drugs and cardiovascular risks: A science advisory from the American Heart Association and American College of Cardiology Foundation[J]. Circulation, 2010,121(16):1868-1877. doi: 10.1161/CIR.0b013 e3181d34114.
  • 10Ciudin A, Hemanadez C, Simo R. Update on cardiovascular safety of PPAR-gamma agonists and relevance to medieinal chemistry and clinical pharmacology[J]. Curr Top Med Chem, 2012,12(6):585- 604. doi: 10.2174/156802612799436632.

引证文献2

二级引证文献4

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部